SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells 5,284 Shares of Company Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,284 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $8.12, for a total value of $42,906.08. Following the transaction, the chief technology officer owned 166,887 shares of the company’s stock, valued at approximately $1,355,122.44. This represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Monday, August 24th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.80, for a total value of $44,000.00.
• On Wednesday, August 19th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.20, for a total value of $41,000.00.
• On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.60, for a total value of $38,000.00.
• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.95, for a total value of $34,750.00.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ:SOPH traded down $0.23 on Wednesday, hitting $7.15. The company’s stock had a trading volume of 432,750 shares, compared to its average volume of 308,157. The company has a market capitalization of $599.81 million, a price-to-earnings ratio of -6.22 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a 12 month low of $3.75 and a 12 month high of $8.98. The stock’s 50-day moving average is $7.82 and its two-hundred day moving average is $6.12.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, equities research analysts forecast that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. HC Wainwright boosted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research boosted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00 for SOPHiA GENETICS, suggesting potential upside from recent trading levels if the company meets analyst expectations. SOPHiA GENETICS SA Stock Has Consensus Target Price of $10.00 According to Brokerages
• Neutral Sentiment: A comparison article examined SOPHiA GENETICS against Weave Communications, but the item did not identify a specific new company development or change to SOPH’s outlook. Critical Comparison: Weave Communications vs. SOPHiA GENETICS
• Negative Sentiment: Company insiders collectively sold approximately 82,298 shares worth $668,827, including sales by Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma and other executives. The transactions reduced their individual holdings by roughly 0.15% to 3.55%, creating near-term selling pressure and potentially weighing on investor sentiment. However, all reported sales were pre-arranged and explicitly made to satisfy tax obligations rather than indicating discretionary selling. SEC insider transaction filing

Institutional Trading of SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Maven Securities LTD bought a new stake in SOPHiA GENETICS during the second quarter worth approximately $866,000. AXQ Capital LP bought a new stake in shares of SOPHiA GENETICS during the 2nd quarter worth $119,000. AWM Investment Company Inc. acquired a new position in shares of SOPHiA GENETICS in the 2nd quarter worth $9,809,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of SOPHiA GENETICS in the 2nd quarter worth $567,000. Finally, Royal Bank of Canada raised its position in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the period. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.